Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Buy" From Analysts
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Buy" From Analysts
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) has been assigned an average recommendation of "Buy" from the eleven brokerages that are presently covering the stock, Marketbeat.com reports. Eight analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $46.56.
據Marketbeat.com報道,納斯達克(股票代碼:ZNTL-GET Rating)目前涵蓋該股的11家券商已給予該公司“買入”的平均推薦。八位分析師對該股的評級為買入。在過去一年對該股進行評級的券商中,1年的平均目標價格為46.56美元。
Several research firms recently weighed in on ZNTL. Oppenheimer cut their price target on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Wedbush cut their price target on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an "outperform" rating on the stock in a report on Monday, November 14th. Morgan Stanley cut their price target on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an "overweight" rating on the stock in a report on Friday, November 11th. SVB Leerink cut their price target on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an "outperform" rating on the stock in a report on Thursday, November 10th. Finally, Guggenheim cut their price target on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a "buy" rating on the stock in a report on Friday, November 11th.
幾家研究公司最近對ZNTL發表了看法。在11月10日星期四的一份報告中,奧本海默將Zentalis製藥公司的股票目標價從80.00美元下調至50.00美元,並對該股設定了“跑贏大盤”的評級。韋德布什在11月14日星期一的一份報告中將Zentalis製藥公司的股票目標價從51.00美元下調至32.00美元,並對該股設定了“跑贏大盤”的評級。摩根士丹利在11月11日週五的一份報告中將Zentalis PharmPharmticals的目標價從60.00美元下調至55.00美元,並對該股設定了“增持”評級。SVB Leerink在11月10日週四的一份報告中將Zentalis PharmPharmticals的股票目標價從42.00美元下調至27.00美元,並對該股設定了“跑贏大盤”的評級。最後,古根海姆在11月11日星期五的一份報告中將Zentalis製藥公司的股票目標價從55.00美元下調至28.00美元,並對該股設定了“買入”評級。
Insider Buying and Selling at Zentalis Pharmaceuticals
Zentalis製藥公司的內幕買賣
In other Zentalis Pharmaceuticals news, President Cam Gallagher sold 12,500 shares of the business's stock in a transaction dated Monday, November 7th. The shares were sold at an average price of $23.67, for a total value of $295,875.00. Following the transaction, the president now directly owns 396,885 shares in the company, valued at $9,394,267.95. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 50,000 shares of company stock worth $1,153,375 over the last three months. 19.90% of the stock is currently owned by insiders.
在Zentaris製藥的其他消息中,總裁Cam Gallagher在11月7日星期一的交易中出售了12,500股該公司的股票。這些股票的平均價格為23.67美元,總價值為295,875.00美元。交易完成後,總裁現在直接持有該公司396,885股股份,價值9,394,267.95美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過此超鏈接。過去三個月,內部人士總共出售了5萬股公司股票,價值1,153,375美元。該公司19.90%的股份目前由內部人士持有。
Institutional Trading of Zentalis Pharmaceuticals
Zentaris製藥的制度性交易
Zentalis Pharmaceuticals Price Performance
Zentaris藥品價格表現
NASDAQ:ZNTL opened at $18.28 on Friday. The firm has a 50-day moving average of $21.55 and a 200-day moving average of $24.69. The company has a market cap of $1.04 billion, a PE ratio of -3.87 and a beta of 1.80. Zentalis Pharmaceuticals has a one year low of $17.33 and a one year high of $85.95.
納斯達克:ZNTL上週五開盤報18.28美元。該公司的50日移動均線切入位在21.55美元,200日移動均線切入位在24.69美元。該公司市值為10.4億美元,市盈率為-3.87,貝塔係數為1.80。Zentalis PharmPharmticals的一年低點為17.33美元,一年高位為85.95美元。
Zentalis Pharmaceuticals Company Profile
Zentaris製藥公司簡介
(Get Rating)
(獲取評級)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.
Zentalis製藥公司是一家臨牀階段的生物製藥公司,專注於發現和開發用於治療各種癌症的小分子療法。它的主要候選產品包括WEE1的抑制劑ZN-c3,這是一種蛋白質酪氨酸激酶,正處於治療晚期實體腫瘤的第二階段臨牀試驗;作為單一療法治療晚期實體腫瘤的第1/2階段臨牀試驗,以及正在進行的與鉑耐藥卵巢癌患者的聯合化療的1b階段臨牀試驗;以及腫瘤不可知的、可預測的生物標記物的第二階段單一治療試驗。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Zentalis Pharmaceuticals (ZNTL)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取StockNews.com關於Zentalis製藥的研究報告(ZNTL)
- MarketBeat:回顧一週12/19-12/23
- 這些鋼鐵製造商理應在2023年觀察名單上佔有一席之地
- 通脹降温,標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Zentaris製藥日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Zentalis製藥公司和相關公司的最新新聞和分析師評級的每日簡要摘要。